Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

Eligibility Criteria

• * Able to provide written consent
• * Patient has given permission to give tumor/blood sample for research testing
• * Histological confirmation of squamous cell carcinoma or adenosquamous carcinoma
• * Known HPV status defined as positive staining for p16 on immunohistochemistry (IHC) or DNA in situ hybridization (ISH) for HPV
• * Willingness to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
• * Consent to allow blood specimens to be shared with potential external collaborators
• * Cohort #1: Surgery alone for early stage disease (Federation of Gynecology and Obstetrics \[FIGO\] stage IA-IB1)
• * FIGO 2019 stage IA1, IA2, IB1
• * Plan to undergo surgery including but not limited to trachelectomy, radical hysterectomy, and lymph node dissection
• * Cohort #2: Post-operative radiation +/- chemotherapy for intermediate and high risk factors
• * Any FIGO stage
• * Status post any definitive surgical procedure (e.g. radical hysterectomy and lymph node dissection) and on final pathology found to have risk factors:
• * Intermediate risk: Lymphovascular space invasion (LVSI), deep cervical stromal invasion, tumor size \> 4 cm
• * High risk: pelvic or para-aortic lymph nodes, parametrial invasion, positive surgical margins
• * Plan to undergo pelvic +/- para-aortic radiotherapy with or without chemotherapy per standard of care
• * Cohort #3: Definitive chemoradiotherapy for locally advanced disease (FIGO stage IB2-IIIC)
• * FIGO 2019 Stage IB2-IIIC or not a surgical candidate
• * Plan to undergo definitive chemoradiotherapy including external beam radiotherapy, brachytherapy, and chemotherapy
• * Cohort #4: Systemic treatment for recurrent or metastatic disease
• * Any recurrence (local, regional, or distant) after prior treatment for cervical cancer
• * Metastases at first diagnosis without prior treatment
• * Other active malignancy =\< 2 years prior to registration.
• * EXCEPTIONS: Non-melanotic skin cancer
• * NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for cancer
• * Pregnancy or lactation
• * Inability on the part of the patient to understand the informed consent to be compliant with the protocol